Peter Kauffman, PA
Physician Assistant · Pinehurst, NCNPI 1144251364
Payments from drug & device makers
Across 436 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Inspire Medical Systems, Inc.$2K
- GSK$1K
- Jazz Pharmaceuticals Inc.$882
- Insmed, Inc.$678
- Sanofi$480
- plus $4K from 30 others
What the payments were for
- Travel & lodging$7326%
- Food & beverage$10,68591%
- Education$2993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 89 | $2,674 |
| Inspire Medical Systems, Inc. | 33 | $1,706 |
| GSK | 75 | $1,085 |
| Jazz Pharmaceuticals Inc. | 28 | $882 |
| Insmed, Inc. | 27 | $678 |
| Sanofi | 21 | $480 |
| Regeneron Healthcare Solutions, Inc. | 13 | $450 |
| Boehringer Ingelheim | 22 | $422 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $349 |
| Mallinckrodt Hospital Products Inc. | 13 | $297 |
| Grifols USA, LLC | 12 | $294 |
| Mylan Specialty L.p. | 14 | $285 |
| Lilly USA, LLC | 5 | $276 |
| Actelion Pharmaceuticals US, Inc. | 6 | $269 |
| Avadel CNS Pharmaceuticals, LLC | 8 | $256 |
| Amgen | 10 | $179 |
| Baxter Healthcare | 4 | $155 |
| Pulmonx Corporation | 1 | $125 |
| Merck | 4 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Viatris Specialty LLC | 3 | $72 |
| Philips North America LLC | 4 | $71 |
| Verona Pharma, Inc. | 3 | $70 |
| Electromed, Inc. | 5 | $66 |
| Pfizer | 3 | $65 |
| United Therapeutics Corporation | 3 | $62 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Novartis | 2 | $42 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Abbott | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$969
- FASENRA$364
- DUPIXENT$265
- ZEPBOUND$250
- AIRSUPRA$250
- TEZSPIRE$249
- BREZTRI$125
- Arikayce$125
- CHARTIS CATHETER$125
- ZEPHYR ENDOBRONCHIAL VALVE$125
- PULMONX CHARTIS TABLET CONSOLE$125
- ZEPHYR DELIVERY CATHETER$125
- LUMRYZ$125
- UPTRAVI$124
- OPSUMIT$124
- XYWAV$109
How this compares
$11,716 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 68 | $295,914 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 199 | $171,327 |
| Breo ElliptaFluticasone/Vilanterol | 148 | $92,464 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $74,387 |
| NucalaMepolizumab | 15 | $64,203 |
| Spiriva RespimatTiotropium Bromide | 58 | $52,323 |
| Dupixent PenDupilumab | 12 | $44,385 |
| Spiriva HandihalerTiotropium Bromide | 33 | $23,608 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 122 | $21,389 |
| Modafinil | 27 | $15,146 |
| Arnuity ElliptaFluticasone Furoate | 36 | $12,751 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $11,838 |
| Advair DiskusFluticasone Propion/Salmeterol | 32 | $11,666 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $10,468 |
| AirsupraAlbuterol Sulfate/Budesonide | 15 | $10,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Airsupra, Symbicort | $2,674 | $390,031177 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta, Anoro Ellipta | $1,085 | $361,733437 claims |
| Boehringer IngelheimSpiriva Respimat | $422 | $52,32358 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl | $12 | $3,51312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Pinehurst
- Robert ThomasPinehurst$60K
- Grant BischofPinehurst$25K
- Sara EbelPinehurst$22K
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.